Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report. by Singh, Sukhmani et al.
UCSF
UC San Francisco Previously Published Works
Title
Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans 
progressiva treated with the RAR-γ agonist palovarotene: a case report.
Permalink
https://escholarship.org/uc/item/05n1j5rg
Journal
BMC musculoskeletal disorders, 21(1)
ISSN
1471-2474
Authors
Singh, Sukhmani
Kidane, Joseph
Wentworth, Kelly L
et al.
Publication Date
2020-04-03
DOI
10.1186/s12891-020-03240-2
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
CASE REPORT Open Access
Surgical management of bilateral hip
fractures in a patient with fibrodysplasia
ossificans progressiva treated with the RAR-
γ agonist palovarotene: a case report
Sukhmani Singh1, Joseph Kidane2, Kelly L. Wentworth1, Daria Motamedi3, Saam Morshed4,
Andrew E. Schober5 and Edward C. Hsiao1*
Abstract
Background: Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare disorder marked by painful, recurrent flare-
ups and heterotopic ossification (HO) in soft and connective tissues, which can be idiopathic or provoked by
trauma, illness, inflammation, or surgery. There are currently no effective treatments for FOP, or for patients with
FOP who must undergo surgery. Palovarotene, an investigational retinoic acid receptor-γ agonist, offers a potential
avenue to prevent HO formation.
Case presentation: The patient is a 32 year-old male, who at age 29 enrolled in a study evaluating palovarotene to
prevent HO formation in FOP. One year after starting palovarotene, he fell resulting in a left intertrochanteric
fracture. He underwent intramedullary nailing of the femur shaft with screw placement at the distal femur. After
surgery, he received palovarotene at 20 mg/day for 4 weeks, then 10 mg/day for 8 weeks. Imaging 12 weeks after
surgery showed new bridging HO at the site of intramedullary rod insertion and distal screw.
Nine months after the left hip fracture, the patient had a second fall resulting in a subdural hematoma, left parietal
bone fracture, and right intertrochanteric fracture. He underwent intramedullary nailing of the right hip, in a
modified procedure which did not require distal screw placement. Palovarotene 20 mg/day was started at fracture
occurrence and continued for 4 weeks, then reduced to 10 mg/day for 8 weeks. HO also formed near the insertion
site of the intramedullary rod. No HO developed at the right distal intramedullary rod. After each fracture, the
patient had prolonged recurrent flare-ups around the hips.
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Conclusion: Surgery is only rarely considered in FOP due to the high risks of procedural complications and
potential for inducing HO. This case emphasizes the risks of increased flare activity and HO formation from injury
and surgery in patients with FOP. The efficacy of HO prevention by palovarotene could not be assessed; however,
our observation that palovarotene can be administered in an individual with FOP following surgery with no
negative impact on clinical fracture healing, osteointegration, or skin healing will help facilitate future trials testing
the role of palovarotene as a therapy for HO.
Keywords: Fibrodysplasia ossificans progressiva (FOP), Palovarotene, Retinoic acid receptor (RAR) agonists,
Heterotopic ossification (HO), Prophylaxis, Hip fracture, Repair surgery, Case report
Background
Heterotopic ossification (HO) is a severe condition of
bone formation in an inappropriate anatomic location,
often triggered by trauma or other inflammatory pro-
cesses [1]. One genetic condition that leads to
massive and progressive HO is fibrodysplasia ossifi-
cans progressiva (FOP), a rare debilitating disease
resulting from mutations in the Activin A Receptor
Type 1 (ACVR1)/Activin-like Kinase 2 (ALK2) gene
encoding for a type 1 membrane receptor for bone
morphogenetic proteins (BMPs) [2]. This mutation
leads to over-activation of downstream SMAD path-
ways which trigger the formation of excessive hetero-
topic endochondral bone [3].
FOP may be diagnosed in childhood by findings of
malformations of the great toes combined with unusual
indurated masses that eventually form bone. Patients
with FOP develop painful soft tissue swellings (“flare-
ups”), which can be precipitated by trauma, injury, ill-
ness, or other inflammatory processes. These flare-ups
can progress to HO and progressive loss of mobility [4,
5]. For this reason, any type of injury, including iatro-
genic injury from medical or surgical procedures, must
be minimized. Current therapies to reduce disease flare-
ups are limited, with steroids and non-steroidal anti-
inflammatory agents (NSAIDs) currently being used for
symptom management though they may not alter dis-
ease course [5].
Palovarotene is a retinoic acid receptor (RAR) γ agon-
ist that can reduce heterotopic bone formation in mouse
models of FOP [6]. Studies in mice have also suggested
that retinoids may be associated with a transient delay in
fracture healing which may have implications for pa-
tients on treatment [7]. Ongoing clinical trials suggest
that palovarotene may be administered as episodic treat-
ments for flare-ups (NCT02190747, NCT03312634).
Here we present a case study showing that routine frac-
ture healing after surgical repair of two hip fractures in
an individual with FOP on palovarotene treatment
showed no clinically significant delay in fracture healing
and that the medication was not associated with any un-
expected adverse events.
Case presentation
The patient is a 32 year-old male at the time of this case
report with a history of asthma, Gilbert’s disease, and
hypertension who was diagnosed with FOP at age 9 after
presenting with a limp. At presentation, he had calcifica-
tion in his left sartorius muscle on imaging. He subse-
quently had FOP bone formation flare-ups with
increasing frequency leading to reduced mobility, though
he remained independent for activities of daily living
and ambulated without assistive devices. The major
joints affected were his spine, jaw, shoulders, right hip,
and bilateral ankles. From his teens to his mid-twenties
flare-ups were treated with a prednisone taper following
standard-of-care guidelines [8]. Between ages 13 to 28
years he also received 4-week courses of thalidomide for
flare-ups as part of a clinical study, for its anti-
angiogenic effect, but without major clinical changes in
his disease course [9]. He received his first dose of zole-
dronic acid, in an effort to reduce flare-ups through pos-
sible anti-inflammatory effects [10], at approximately age
19 years, then received 8 doses between the ages of 25 to
29 years and yearly thereafter.
At age 29 years, he enrolled in the phase 2 randomized
control trial of palovarotene for the treatment of preoss-
eous flare-ups in FOP (NCT02190747). He was having
approximately 4 flares per year at the time of enroll-
ment. He completed 6 weeks on the study protocol and
subsequently enrolled in an open-label extension trial
for the use of palovarotene (episodic dosing of 20 mg/
day for 4 weeks, then 10mg/day for 8 weeks) for flare-
ups (NCT02279095). He then transitioned to a chronic
treatment arm with palovarotene (5 mg/day) along with
the episodic treatment with palovarotene for flare-ups.
In addition to palovarotene, he received prednisone 110
mg/day for 4 days followed by a taper for his flare-up
treatments. His treatment course and flare-up activity in
the open-label extension trial is depicted in Fig. 1. Dur-
ing this time, the patient received topical prophylaxis
with Aquaphor barrier ointment, triamcinolone 0.1% for
retinoid skin reactions such as rash and dry skin, and
artificial tears, for managing the most common potential
mucocutaneous side effects of palovarotene.
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One year after starting chronic palovarotene treatment,
the patient had a fall resulting in a left inter-trochanteric
fracture (Fig. 2). He was on palovarotene 5mg/day, and
had just completed a palovarotene/prednisone treatment
cycle two weeks prior. Palovarotene 5mg/day treatment
was interrupted for one day after the fall then resumed at
5mg/day until his surgery. Immediately after the fall, he
was started on high-dose prednisone (110mg/day) to re-
duce inflammation at the surgical site [5]. High-dose pred-
nisone was continued until 3 days post-op and then
tapered by 10mg/day until completely stopped. To
minimize the risk of flare-ups, intravenous (IV) treatments
were discontinued as early as possible and aspirin (81mg
twice daily) was used for deep vein thrombosis prophy-
laxis. Celecoxib 100mg twice daily was started based on
prior studies indicating that NSAIDs may reduce HO for-
mation after hip surgery [11].
Surgery was pursued to stabilize the fracture, reduce
pain, and preserve potential mobility. The surgical ap-
proach was designed to minimize soft tissue trauma but
provide adequate access to safely stabilize the fracture in a
way that would allow immediate weight-bearing. The pa-
tient underwent intramedullary nailing of the femur shaft
with screw placement at the distal femur 9 days after the
fall, after transfer to University of California, San Francisco
(UCSF). Asleep nasal fiberoptic intubation with a small
tube was carefully performed after induction of general
anesthesia. This approach was used to minimize trauma
which could trigger an obstructing neck flare leading to
cervical spine fusions, ankyloses of the temporomandibu-
lar joint, or airway compromise. Methylprednisolone 50
mg IV was administered at the time of surgery to decrease
the risk of airway edema and 2 g cefazolin was adminis-
tered prior to incision for antibiotic prophylaxis. Bony
prominences were carefully padded to prevent pressure-
induced flare-ups. The jaw was also propped closed with
foam tucked under the chin to prevent stretching and in-
jury to the masseter muscles. After surgery, he was started
on prednisone 50mg twice daily for 1 day and then ta-
pered by 10mg/day until completion.
Manual traction was employed to position the hip to
restore length; however, as varus was still noted, a pin
Fig. 1 Timeline of palovarotene dosing in the open label phase of the PVO-1A-202B trial. Flare-up dosing, flare site, and fracture events are noted
Fig. 2 X-Ray imaging of the left hip: (a) X-Ray of the left pelvis at the time of the subtrochanteric fracture [arrow]. (b) X-Ray of the knee 4 months
after surgery with HO at the site of distal screw insertion [arrow]. (c) Brooker class D HO at the rod insertion site 4 months after surgery [arrows]
and after 9 months (d). (e) X-ray showing matured HO formation at 12 months [arrow]
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was placed through the planned skin incision for nail in-
sertion from the top of the greater trochanter across the
base of the femoral neck fracture into the calcar in order
to anatomically reduce the displaced fracture. Afterward,
a threaded tip guidewire was placed to guide trochan-
teric entry of the nail. A 4 cm incision was made for pas-
sage of the trocar and entry reamer and a ball-tipped
guidewire was placed across the fracture and to the level
of the superior pole of the patella within the medullary
cavity of the femur. This was followed by passage of ser-
ial reamers starting at 10 mm and advancing in 1 mm in-
crements up until endosteal chatter was obtained at 15
mm. The final reaming diameter was 15.5 mm. A 13mm
trochanteric entry cephalomedullary nail was attached to
the insertion jig and inserted (Trochanteric Fixation
Nail, DePuy Synthes, West Chester, Pennsylvania). Using
fluoroscopic imaging, the nail was positioned to allow
for passage of a spiral blade in a central position within
the femoral head and neck. A guidewire was passed
using imaging guidance into the subchondral bone of
the femoral head and the spiral blade was inserted over
the guidewire through the proximal aspect of the nail via
a second lateral proximal thigh incision. A single distal
interlocking screw was placed using freehand technique
via a 2 cm incision on the distal lateral thigh. The pos-
ition was confirmed on fluoroscopic imaging. Care was
taken to irrigate any bone from the soft tissues at the
nail, spiral blade, and distal interlocking screw site in
order to minimize the risk of HO.
After surgery, flare-up based palovarotene dosing was
started at 20 mg daily for 4 weeks and then decreased to
10mg/day for an additional 8 weeks per the study proto-
col. Due to repeated flare-ups he was not able to de-
crease his palovarotene to the 5 mg/day chronic dosing.
Post-operative celecoxib was continued.
Radiologic and clinical assessments did not show any
delay in fracture healing. Over the subsequent 2 months,
the patient showed progressive clinical loss in the range
of motion of the left hip and required the use of a cane
for ambulation. A review of X-ray images at the time of
the fracture showed no evidence of HO at the left hip
(Fig. 2a). Radiologically, HO and a callus were evident
around the distal screw by the left knee after 4 months
(Fig. 2b). In addition, HO at the left hip was evident by
9 weeks and fully matured by 14 weeks (Fig. 2c). Brooker
class D HO was clearly present on imaging at 9 months
after surgery and matured at 12 months after surgery
[12] (Fig. 2d-e).
Nine months after the left femoral fracture, the patient
was on palovarotene 10mg/day after a separate series of
flare-ups. Four days after tapering to palovarotene 10
mg/day dose, he had an intercurrent flare in his chest
that was treated with palovarotene 20 mg/day. The pa-
tient had a second fall 4 days later, where he lost his
balance and fell backwards resulting in a subdural
hematoma, left parietal bone fracture, and a displaced
right sub-trochanteric femoral fracture. Palovarotene
was continued at 20 mg/day per a study modification
allowing for prophylactic treatment of a physical injury,
and the patient received prednisone 100 mg/day for 4
days followed by a taper by 20 mg every 2 days, starting
on the day of the injury.
The risks and benefits of non-operative management
versus surgery were discussed again with the patient. Ad-
equate pain control was difficult during the non-operative
treatment. After transfer to UCSF and stabilization of his
other injuries, he underwent intramedullary nailing of the
right hip 10 days after sustaining the fracture.
Despite straightforward asleep nasal fiberoptic intub-
ation during the prior surgery, repeat attempt at nasal
intubation for this procedure was difficult, requiring
multiple attempts and eventual oral intubation with a
video laryngoscope. Once his airway was stabilized, the
identical long cephalomedullary nail was used. Antibiotic
prophylaxis with 2 g cefazolin at the time of incision was
again used. However, on the right side we avoided the
use of a distal interlocking screw as its use is not re-
quired for successful fixation and stabilization of such
injuries and may have contributed to the HO around the
knee after his prior surgery. The intertrochanteric frac-
ture was noted to be in some degree of varus and the
femur minimally shortened, but in order to minimize
soft tissue injury, an open reduction was not performed.
No traction pins or additional bony manipulation was
performed. Under fluoroscopic imaging, the appropriate
incision was mapped out proximal to the greater tro-
chanter and in line with the femur in the sagittal plane.
A threaded tip guidewire was once again positioned to
direct nail entry using fluoroscopic imaging. An entry
reamer was inserted with as little trauma as possible
through the soft tissues and passed into the proximal
femur. This was followed by placement of a ball-tipped
guidewire into the distal aspect of the femur. A 15.5 mm
reamer was attached to the reaming drive and passed in
a single pass without any evidence of compromise to the
surrounding endosteal surfaces of the femur. A 13mm
trochanteric fixation nail was inserted in an antegrade
fashion. A lateral cortical drill and reamer was used to
open up the canal for passage of the spiral blade. Fluor-
oscopy was used to confirm restoration of alignment
and correct positioning of all implant components. He
remained intubated after the procedure and was extu-
bated without incident on post-operative day 1. Fortu-
nately, he suffered no significant complications from a
longer duration of intubation or HO formation in the
temporomandibular joint or surrounding tissues.
Fracture healing was not delayed based on clinical im-
aging; however, the patient showed continued loss of
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mobility, requiring the use of a walker and wheelchair.
Again, the patient showed multiple and prolonged FOP
flare-up activity, resulting in a significant increase in the
number of flares/year. The right hip showed new devel-
opment of Brooker class B HO at the greater trochanter,
near the insertion site of the intramedullary rod, by 3
months after surgery (Fig. 3).
Discussion and conclusions
Here, we describe the first case using the RAR-γ agonist,
palovarotene, in a patient with FOP undergoing hip frac-
ture repair surgery. It has been shown that chondrogen-
esis requires transcriptional repression of RARs and that
retinoic acid receptor activation blocks chondrogenesis.
Activation of RAR-γ, expressed in chondrogenic cells
and chondrocytes, can selectively inhibit HO [7, 13, 14].
Initial studies by Shimono et al. with RAR agonists in
mouse mesenchymal stem cells showed decreased phos-
phorylation of SMAD1, SMAD5, and SMAD8 and over-
all SMAD levels, suggesting a reduction in BMP
signaling [7]. This led to studies of the use of palovaro-
tene in trauma-induced mouse models of FOP. Chakka-
lakal et al. demonstrated a significant reduction in HO
formation and fibroproliferative responses in knock-in
Acvr1R206H mice when palovarotene was administered
after cardiotoxin induced injury [6]. Joint and limb mo-
bility was preserved in these palovarotene-treated mice.
Phase 2 (NCT02279095) and 3 clinical trials
(NCT03312634) to test palovarotene in patients with
FOP are currently on-going. A prior study of palovaro-
tene for treatment of emphysema showed that the drug
was well tolerated with skin, gastrointestinal, eye, and
respiratory mucocutaneous side effects being most com-
mon at the dosing regimen used in that patient popula-
tion [15].
Despite the known link between retinoids and skin ad-
verse events, the patient described here had normal
wound healing and showed no unexpected or major skin
adverse events. The patient received topical prophylaxis
with Aquaphor barrier ointment, triamcinolone 0.1% for
retinoid skin reactions such as rash and dry skin, and
artificial tears, for managing the most common potential
mucocutaneous side effects. Notably, the patient showed
no delayed healing of his skin wound or tissue after
either surgery. Thus, the high-dose retinoid was well tol-
erated by this patient in the setting of two surgeries.
Palovarotene did not have a significant or negative im-
pact on clinical fracture healing or osteointegration with
the repair hardware.
The bilateral fragility fractures were likely multifactor-
ial in origin. The patient had a history of prolonged and
high dose prednisone throughout childhood and adult-
hood. CT bone densitometry performed after the first
fracture showed a lumbar spine T-score 3.8 standard de-
viations below the reference population, consistent with
a diagnosis of severe osteoporosis. This likely arose from
both decreased weight bearing as well as steroid-induced
osteoporosis despite having received IV zoledronate on a
regular basis. Osteoporosis may be a major clinical fea-
ture of advanced FOP since severe bone thinning is
clearly evident in the two FOP skeletons housed in the
Mutter Museum. Shifts in calcium from the native skel-
eton to inappropriate sites have also been reported in
patients with severe atherosclerosis [16, 17], suggesting
that shifts in calcium stores may be a contributor to
FOP related degeneration of the native skeleton. In
addition, the frequent and long-term use of bisphospho-
nates in this patient raised the possibility that the patient
was predisposed to atypical-like femur fractures. In our
patient, he reported no prodrome symptoms, and the
fractures occurred in the setting of clear trauma.
In general, patients with FOP should avoid surgery un-
less absolutely necessary because of the high risks of
complications from intubation, the surgical procedure,
and triggering of FOP flares. Although the patient was
successfully intubated, the second intubation was ex-
tremely difficult and emphasizes the high risks of surgery
on FOP patients. It is unclear whether this was due to
the presence of skull fractures, residual facial soft tissue
swelling, HO from the prior intubation, or some com-
bination thereof. Fortunately, he suffered no significant
complications from a longer duration of intubation or
HO formation in the temporomandibular joint or sur-
rounding tissues as a result. In addition, HO formed in
areas near surgical interventions such as the hardware in-
sertion tract through the soft tissues and around the
Fig. 3 X-Ray imaging of the right hip: (a) Intertrochanteric fracture
noted by arrow. There is longstanding osteochondromatosis at the
right femoral head [arrowheads]. (b) X-ray of the femur 13 weeks
after surgery show post-surgical hardware and demonstrate Grade B
HO at the left femoral head [arrow]
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locking screw above the left knee. The prolific formation of
HO after surgeries in FOP has been described before [18].
The formation of HO at the hardware insertion sites
raises the concern that the reaming process may have con-
tributed to HO formation. The physiologic effects of canal
reaming can disrupt cortical blood flow but appears to be
offset by increased circulation to the periosteum and
surrounding skeletal muscle with subsequent revasculari-
zation that ultimately promotes healing [19, 20]. Investiga-
tions into reaming debris have showed elevated levels of
FGF, PDGF, IGF-1, TGF-B and BMP-2 [21]. While these
factors might usual induce recruitment and migration of
progenitor cells into the fracture, stimulating osteogenesis
and angiogenesis, in a patient with FOP this may lead to
further activation of the ACVR1/Smad cascade. This
stimulation could, in theory, contribute to HO formation
in patients with FOP; however, as there was a concern for
nonunion, stabilization of the fracture sites was the high-
est priority which led to the decision to proceed with
reaming. To minimize trauma, biopsies were not obtained
from the fracture sites.
Notably, the patient developed a significant increase in
flare activity after each fall. The occurrence of multiple
flares after the trauma likely resulted in further HO for-
mation, and makes it difficult to assess whether palovar-
otene reduced HO formation since the inflammatory
stimuli were persistently present. In addition, the second
fall involved multiple injuries consistent with poly-
trauma, which in and of itself is associated with in-
creased risks of heterotopic ossification [22] such as in
survivors of high-energy trauma. Although it is difficult
to compare the left and right fracture events, there was
significantly less heterotopic ossification on the right
side (second fracture) as compared to the left side
(which involved more surgical manipulation). It is worth
noting that minor clinically evident HO formation was
eventually detectable after the extensive manipulation of
the temporomandibular joint and upper airways during
the difficult intubation for the second surgery. Whether
administration of palovarotene played a role in avoid-
ance of facial and airway HO formation is unknown.
These observations, as well as the finding of multiple
subsequent “after-shock” flares after the primary injury,
further reinforces the importance of judicious surgical
management for patients with FOP and the likely correl-
ation between the degree of injury and the severity of
the subsequent HO. These observations also suggest that
future therapeutic strategies to control the inflammatory
response after the inciting injury may be useful consider-
ations for breaking the prolonged cycles of flares re-
ported by FOP patients, and that these cycles may
increase the risk of heterotopic bone formation.
Though this case involves a patient with a genetic
form of HO, testing of RAR-γ agonists in non-genetic
forms of HO may still be beneficial. Non-genetic HO
has been demonstrated to occur in adults, typically in
their second and third decades, after a history of
trauma or repetitive mechanical stress and can range
from being clinically unnoticeable to resulting in
chronic pain and high morbidity [23]. HO has been
noted particularly in the setting of combat related in-
jury such as post-blast injury or extremity amputa-
tion, where the prevalence of HO formation can
approach 65% of patients [22]. Orthopedic surgery,
including hip arthroplasty, fracture, traumatic brain or
spinal cord injury, and severe burns are risk factors
in the development of heterotopic ossification. The
pathogenesis is thought to be similar to HO develop-
ment in FOP, where inflammation leads to recruit-
ment of progenitor cells and ultimately endochondral
or intramembranous ossification but there are mul-
tiple pathways involved [24]. Studies in non-genetic
HO models are limited. A selective RAR-α agonist
was tested in an rhBMP-2 mouse model and reduced
heterotopic cartilage, bone and expression of chon-
drogenic genes [25]. A study of palovarotene in a
blast-related traumatic injury mouse model decreased
HO formation by 50–60% and decreased ectopic
chondrogenesis, osteogenesis and angiogenesis at the
injury site [26]. Palovarotene showed slight inhibitory
effects on wound healing, but this was not statistically
significant. Thus, RAR-γ agonism may still be benefi-
cial for non-genetic forms of HO.
Current treatment for FOP [5] is largely limited to avoid-
ance of trauma and supportive measures such as glucocor-
ticoids for flare management, COX-2 inhibitors, non-
steroidal anti-inflammatory, bisphosphonates, mast cell in-
hibitors, and potentially imatinib [27] or IL-1 inhibitors
[28]. Surgery should still be avoided in FOP patients when-
ever possible; however, if surgical intervention is needed,
the most minimally invasive approach should be used.
Our patient demonstrates that careful treatment of a
patient with FOP undergoing surgery with a retinoic
acid receptor agonist such as palovarotene can be well
tolerated with minimal side effects. However, major
trauma may increase FOP flare activity that would com-
plicate end-point assessments for clinical trials of medi-
cations for surgical treatment in FOP. Thus, fracture
healing, flare activity, and HO formation are key end-
points that should be assessed in clinical trials involving
surgical outcomes in novel FOP therapies [29]. Finally, it
remains to be seen if palovarotene or other blockers of
chondrogenic ossification may be useful for the treat-
ment of non-genetic HO in more common conditions
such as hip arthroplasty.
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